FLT180a (verbrinacogene setparvovec), a liver-directed adeno-associated virus (AAV) gene therapy has been tried in a phase I-II clinical trial to normalize factor IX levels in patients with hemophilia B. The therapy has shown promising results indicating the change in the future of patients born with hemophilia B. This genetic therapy uses a synthe
1045 Reached1 Comments
Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Pancytopenia, a rare presentation of hyperthyroidism
832 Reached2 Comments
Female with History of Amenorrhoea
3103 Reached10 Comments11 Likes